Clover Corporation Outlines Path to US Growth After FY26 Profit Jumps 50%
Key Takeaways
- Clover Corporation FY26 Results beat the company's own guidance range of $92–96m, with revenue landing at $97.4m — up 13.3% on FY25's $86.0m.
- NPAT rose 50% to $10.5m and EBITDA grew 39% to $17.0m, with gross margin expanding sharply from 30.5% to 35.5% driven by product mix and vertical integration.
- New and innovative products now represent approximately two-thirds of revenue, up from 40% in 1H 2024, with gross margin moving in lockstep from 27% to the mid-30s over the same period.
- Operating cash flow declined to $4.4m from $8.3m due to a deliberate $19.8m inventory build to $43.9m, with all interest-bearing liabilities fully repaid and $7.2m cash retained.
- The Board expects 1H FY27 revenue to be ahead of the prior corresponding period, with CholineXcel™ commercialisation and US nutraceuticals market development identified as the primary growth levers.
FY26 results highlight: revenue, earnings and margin all beat expectations
In its September 2026 investor presentation, Clover Corporation revealed a standout full-year result across every key financial metric. CEO Peter Davey and CFO Andrew Allibon outlined revenue of $97.4m, ahead of the company’s own guidance range of $92–96m and up 13% on FY25’s $86.0m, with gross margin expanding sharply to 35.5% from 30.5% the prior year.
The earnings lift was equally material. NPAT rose 50% to $10.5m (from $7.0m), EBITDA grew 39% to $17.0m, and return on equity improved 370 basis points to 13.4%. The Board declared a final fully franked dividend of 1.25 cents per share, and the company closed the year with $7.2m cash and no interest-bearing liabilities.
| Metric | FY26 | FY25 | Change |
|---|---|---|---|
| Revenue | $97.4m | $86.0m | +13.3% |
| Gross Profit | $34.6m | $26.2m | +32% |
| Gross Margin % | 35.5% | 30.5% | |
| EBITDA | $17.0m | $12.2m | +39% |
| EBITDA % | 17.5% | 14.2% | |
| NPAT | $10.5m | $7.0m | +50% |
| EPS (cps) | 6.3 cps | 4.2 cps | +2.1 cps |
| ROE (annualised) | 13.4% | 9.7% | +370 bps |
Management attributed the result to consistent execution of the company’s long-term growth strategy, with gross margin improvement driven by innovation, product mix, and increased benefits from vertical integration.
When big ASX news breaks, our subscribers know first
How innovation and product mix drove a three-year margin transformation
For investors trying to understand what is really driving Clover’s margin expansion, the answer comes down to two structural factors: product mix and vertical integration. These are not one-year tailwinds — the presentation detailed a multi-year transformation that is visible in every half-year result.
New products now represent nearly two-thirds of revenue
“Product mix” in Clover’s context refers to the shift away from base commodity-style nutritional ingredients toward higher-margin new and innovative products such as differentiated ARA powders and CholineXcel™. As the proportion of revenue generated by these new products rises, so does the margin the company earns on each dollar of sales.
The stacked bar chart data presented across six half-year periods tells a consistent story:
- 1H 2024: New products 40% of revenue, gross margin 27%
- 2H 2024: New products 44% of revenue, gross margin 27%
- 1H 2025: New products 50% of revenue, gross margin 27%
- 2H 2025: New products 57% of revenue, gross margin 33%
- 1H 2026: New products 65% of revenue, gross margin 36%
- 2H 2026: New products 64% of revenue, gross margin 35%
The pattern is clear: as new products moved from 40% to roughly two-thirds of revenue over three years, gross margin moved in lockstep from 27% to the mid-30s. Innovation is compressing unit costs and lifting pricing power simultaneously — volume growth alone does not produce that outcome.
Vertical integration locking in structural advantages
The second pillar is vertical integration, which means Clover controls key parts of its own supply chain rather than purchasing inputs on the open market. The presentation highlighted two assets that are generating tangible margin benefits.
Clover’s Ecuador fish oil facility is delivering consistent crude oil supply, with tuna oil representing 30% of total raw material inputs in FY26. Its New Zealand operation, Melody Dairies, is operating at near full capacity and delivering profit margin benefits in line with management’s expectations. Critically, Clover’s external debt has now been fully repaid, meaning the balance sheet benefit of ownership flows through without the drag of interest expense.
Balance sheet, cash flow and the strategic inventory build
Operating cash flow declined from $8.3m in FY25 to $4.4m in FY26, and the presentation addressed this directly. Management characterised the movement as a deliberate strategic decision rather than a sign of business deterioration.
- Inventory increased by $19.8m to $43.9m, reflecting strategic restocking of ARA and fish oil supplies against strong customer forecasts.
- Net working capital rose $7.5m to $49.8m as a result of the inventory build.
- Trade receivables fell from $25.1m to $17.3m, a positive signal indicating improved collections performance.
- All interest-bearing liabilities were fully repaid during FY26, leaving the company with a zero debt position.
- Cash of $7.2m was maintained despite the inventory build and dividends paid of $3.3m during the year.
| Working Capital Item | FY26 $m | FY25 $m | Change $m |
|---|---|---|---|
| Trade Debtors | 17.3 | 25.1 | (7.8) |
| Inventory | 43.9 | 24.1 | +19.8 |
| Trade Creditors & Payables | (11.4) | (6.9) | 4.5 |
| Net Working Capital | 49.8 | 42.3 | +7.5 |
The presentation noted that the higher inventory level is consistent with management’s expectations and reflects a strategic decision to secure stock to meet indicative customer demand. With zero debt and a clean balance sheet, Clover has the financial flexibility to carry this stock without pressure to liquidate it at unfavourable terms.
The next major ASX story will hit our subscribers first
Growth priorities: CholineXcel™, USA nutraceuticals and FY27 outlook
The presentation’s forward-looking section outlined three key growth levers management expects to drive the next phase of earnings expansion.
CholineXcel™: from patent to commercial scale
CholineXcel™ is a patented flowable powder with broad commercial applications, with near-term focus on the infant formula and nutraceutical market. The intellectual property position is advancing, with the patent now registered and a PCT application lodged — full patent protection is typically granted in 4–8 years, providing a long commercialisation runway.
Customer product trials (non-infant) commenced in Q1 FY26, and packaging formats and fill rates are being optimised ahead of higher production rates. Management outlined that a review of larger-scale manufacturing options has commenced, with tolling, joint venture, and acquisition options being pursued for infant formula applications. This is a genuinely differentiated IP asset, and the commercialisation path management outlined suggests it remains in early-stage development rather than near-term revenue contribution.
USA nutraceuticals: a dedicated growth push
The presentation identified the US as the world’s largest nutraceuticals market, and detailed Clover’s strategy to use its nutraceuticals offering as a spearhead to market broader capabilities — including Gelphorm — to US customers. Clover has employed a dedicated nutraceuticals expert to devise a strategy for the US, assessing supply chain considerations and potential business partners.
Investors should note that business development costs are expected to be expensed as incurred and are anticipated to increase gradually over the next 2–3 years as the US growth strategy matures. The near-term earnings impact will be modest but cumulative.
FY27 guidance: 1H revenue ahead of prior period
The Board’s FY27 outlook, as presented, is positive but measured. Based on current market and global conditions, the Board expects revenue for 1H FY27 to be ahead of the prior corresponding period. Management cited positive momentum from the vertically integrated supply chain and further expansion of the distribution network. Significant investment in the development and ongoing commercialisation of new products is also anticipated.
The six strategic priorities management outlined for FY27 are:
- Choline: market release, customer acceptance, initial orders, and scaled manufacturing and certification
- USA nutraceutical market development
- Continued development of the distributor network
- Investment in facilities and people
- Continued focused innovation to further diversify the product range
- Continue to optimise supply chain and cost structures
Stay Ahead on ASX Nutrition and Specialty Ingredients News
Get FREE breaking ASX announcements delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 30,000+ subscribers who never miss a market-moving update. Click the “Free Alerts” button at Discovery Alert to start receiving alerts the moment news breaks.